Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis

Cancer

Volumn 78, Issue 5, 1996, Pages 991-997

  Kropveld, Arvid ^a   Slootweg, Pieter J ^a   Van Mansfeld, Alphonsus D M ^b   Blankenstein, Marinus A ^a   Hordijk, Gerrit J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

head and neck; laryngeal carcinoma; p53 status; prognosis; radioresistance; radiotherapy; squamous call carcinoma; tumor genetics

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; RADIATION TOLERANCE; RETROSPECTIVE STUDIES;

EID: 0029819034     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960901)78:5<991::AID-CNCR8>3.0.CO;2-F     Document Type: Article

References (48)

1. Lawson W, Biller HF, Suen JY. Cancer of the larynx. In: Meyers EN, Suen JY. Cancer of the head and neck. 2nd ed. New York: Churchill Livingstone, 1989:552-7.
2. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
3. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The role of the p53 tumour suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
4. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
5. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-34.
6. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
7. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
8. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52.
9. Gartenhaus RB, Wang P, Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type 1-transformed lymphocytes after treatment with Adriamycin by using a p53-independent pathway. Proc Natl Acad Sci USA 1996;93:265-8.
10. Liu T, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995;55:3117-22.
11. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
12. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J Pathol 1994;172: 1-4.
13. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
14. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75:765-78.
15. Agoff SN, Hou J, Linzer DIH, Wu B. Regulation of the human hsp70 promotor by p53. Science 1993;259:84-7.
16. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
17. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991;65:1083-91.
18. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-30.
19. Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen C-Y, et al. Characterization of human GADD45, a p53-regulated protein. J Biol Chem 1994;51:32672-7.
20. Fornace AJ Jr., Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, Fargnoli J, et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 1989;9:4196-203.
21. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
22. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
23. 1 arrest. Cell 1994;76:1013-23.
24. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20k regulatory subunit. Nature 1993;366:707-10.
25. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature 1993;366:704-7.
26. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992;71:505-14.
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
28. Spiessl B. TNM-atlas: illustrated guide to the TNM/pTNM-classification of malignant tumors. 3rd ed. New York: Springer-Verlag, 1990.
29. Wright DK, Manos NN. Sample preparation from paraffin embedded tissues. In: Innes MA, Gelfand DH, Sninsky JJ, White TJ, editors. San Diego: Academic Press, 1990:153-8.
30. DiGuiseppe JA, Hruban RH, Offerhaus GJA, Clement MJ, van den Berg FM, Cameron JL, et al. Detection of k-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-95.
31. Top B. A simple method to attach a universal GC-clamp to PCR fragments used for mutation analysis by DGGE. PCR Meth Appl 1992;2:83-5.
32. Myers RM, Maniatis T, Lerman LS. Detection and localisation of single base changes by denaturing gradient gel electrophoresis. Meth Enzymol 1987;155:501-27.
33. Beck JS, Kwitek AE, Cogen PH, Metzger AK, Duyk GM, Sheffield VC. A denaturing gradient gel electrophoresis essay for sensitive detection of p53 mutations. Hum Genet 1993; 91:25-30.
34. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumours. Cancer Res 1993;53:4189-96.
35. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
36. Xu L, Chen YT, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ, et al. Overexpression of p53 protein in squamous cell carcinoma of head and neck without apparant gene mutations. Diag Mol Pathol 1994;3:83-92.
37. Melhem MF, Law JC, El-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146:1170-7.
38. Mak S, Till JE. The effects of X-rays on the progress of L-cells through the cell cycle. Radiat Res 1963;20:600-18.
39. Lowe SC, Bodis S, McClatchy A, Remington L, Eart Ruley E, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
40. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993;53:4776-80.
41. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrest and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994; 54:3718-22.
42. 1 arrest is selectively mediated by the p53-WAF1/CIP1 pathway in human thyroid cells. Cancer Res 1995;55:2075-80.
43. Little JB, Nagasawa H, Keng PC, Yu Y, Li C-Y. Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J Biol Chem 1995;70:11033-6.
44. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 1992;52:6390-3.
45. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-9.
46. Wilson GD, Richman PI, Dische S, Saunders MI, Robinson B, Daley FM, et al. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995;71:1248-52.
47. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992;52:4832-6.
48. Barten M, Ostwald C, Milde-Langosch K, Müller P, Wakusch Y, L̈oning T. HPV DNA and p53 alterations in oropharyngeal carcinomas. Virchows Arch 1995;427:153-7.